COMPASS points Ionis toward hypertriglyceridemia submissions

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said volanesorsen (IONIS-APOCIIIRx) met the primary endpoint in the Phase III COMPASS trial in patients

Read the full 196 word article

User Sign In